Evidence map›Paper›PMID 36824840›Full record

ArticleResearch square2023

Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.

Shuying Liu, Shelly M Xie, Wenbin Liu, Mihai Gagea, Ariella B Hanker, Nguyen Nguyen, Akshara Singareeka Raghavendra, Gloria Yang-Kolodji, Fuliang Chu, Sattva S Neelapu and 4 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Shuying LiuThe University of Texas MD Anderson Cancer Center.
Shelly M XieThe University of Texas MD Anderson Cancer Center.
Wenbin LiuThe University of Texas MD Anderson Cancer Center.
Mihai GageaThe University of Texas MD Anderson Cancer Center.
Ariella B HankerUniversity of Texas Southwestern Medical Center.
Nguyen NguyenThe University of Texas MD Anderson Cancer Center.
Akshara Singareeka RaghavendraThe University of Texas MD Anderson Cancer Center.
Gloria Yang-KolodjiUniversity of South California.
Fuliang ChuThe University of Texas MD Anderson Cancer Center.
Sattva S NeelapuThe University of Texas MD Anderson Cancer Center.
Samir HanashThe University of Texas MD Anderson Cancer Center.
Johann ZimmermannSpexis Ltd.
Carlos L ArteagaUniversity of Texas Southwestern Medical Center.
Debasish TripathyUniversity of Texas Southwestern Medical Center.
The University of Texas MD Anderson Cancer Center · USSouthwestern Medical Center

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36824840
PMCPMC9949251
OpenAlexW4320724755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.